Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.25p +0.42% 60.00p 0 16:35:26
Bid Price Offer Price High Price Low Price Open Price
58.50p 61.50p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -20.53 -26.20 42.9

Silence Therapeutics (SLN) Latest News

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
23/5/201909:50Silence Therapeutics (the old SR Pharma)47,763
06/10/201609:04Gower Productions Presents ....."PREDICTA BID"52
29/5/201310:32Silence Therapeutics - news and views1,412
15/2/201308:57SLN - I see no ships, but I do see 10p looming, ahoy!368

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

Silence Therapeutics Daily Update: Silence Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 59.75p.
Silence Therapeutics Plc has a 4 week average price of 55p and a 12 week average price of 40p.
The 1 year high share price is 175p while the 1 year low share price is currently 40p.
There are currently 71,563,485 shares in issue and the average daily traded volume is 53,132 shares. The market capitalisation of Silence Therapeutics Plc is £42,938,091.
tarlok: So we see how much notice the MM make of FT news article on SLN , price change of 1p
tshirley12: A few questions,would appreciate any comments.Firstly over the last year the share price has fallen from a peak of 250p to less than Arrowheads share price as more or less quadrupled,what is Silence doing that is fundamentally different to justify the crash. What other assets does Silence have other than their.I.P. Is there a danger of Silence running out of funding,and when. As anybody got any idea how much they received from their Alnylam agreement. What happened to ATUO27. As there's no sign of a takeover,are there any possibilities of a merger with anybody. Now waiting on the results from Quark,if this doesn't go as well as hoped, where does that leave us. As I said I would appreciate any comments as I am looking at all avenues before I decide to bail out.
callumross: Well, there is certainly plenty newsflow expected in the next 6 weeks to drive the share price up (or down!). To recap, Quark phase 3 results, High Court case against Alnylam commencing and application for phase 1 trial.
1gw: Interesting to compare the shares on loan position with the share price chart. According to Euroclear, SoL monthly average this year is as follows: 1.4m Jan (average shares on loan) 1.4m Feb 2.6m Mar 4.3m Apr 4.2m May 4.2m Jun 4.1m Jul 3.9m Aug 2.3m Sep So it looks like a significant increase in short positions in March and April (assuming the SoL correlates to short positions) may have helped to knock the shareprice off its 200p perch. hTtps://
tshirley12: Could anyone tell me what has happened in the last couple of weeks for the share price to have dropped about 40 points,or nearly 25%.
1gw: I missed the Nasdaq reference at first glance. Interesting. I get the impression this is a management team with more than half an eye focused on the share price and the potential to support the price with the carefully managed release of information.
1gw: Nice bit of profit-taking on the arwr stake. I wonder what that will do to the arwr share price today? And whether it's all part of the game to get some meaningful dialogue going with arwr?
1gw: I can't help feeling there's an element of SLN investors looking at the ARWR price trajectory and thinking something's happening - and ARWR investors looking at the SLN price trajectory and thinking the same. Hopefully there's some substance behind both moves rather than mutually reinforcing illusions...
1gw: I am surprised we haven't had a rush of short-term players to the bulletin boards, given the share price chart. All the better for the future, perhaps, if the share price has done what it has done without much input from the bulletin boards or twitter.
1gw: ARWR is up around 20% this afternoon - not enough to take me into profit on my holding, but makes the loss look a little less severe. They beat on revenue and earnings, thanks (I think) to the Amgen up-front payments, and also announced an analyst R&D day for September to explain what they're doing. They described the Amgen partnership as working well and said in response to a question that they were interested in similar partnerships with other companies and are optimistic that they can enter into additional strategic partnerships. No obvious follow-through to the SLN share price yet, but perhaps ARWR's spike (on heavy volume) will draw some attention to other companies in the sector.
Silence Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190526 18:59:16